5611
Clinical Sciences
Tuesday, March 4, 2014: 2:00 PM-3:15 PM
Convention Center, Upper Level, Room 8
1.25 CME/ 1.50 CE
Primary Moderators:
Jeffrey G. Demain , MD FAAAAI
Giselle Mosnaim , MD MS FAAAAI
2:00 PM
L16
Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials
Nicola A. Hanania, MD
2:15 PM
L17
Dose-Finding Efficacy and Safety Trial of House Dust Mite Sublingual Immunotherapy Tablet, MK-8237, Using an Environmental Exposure Chamber
Hendrik Nolte, MD, PhD
2:30 PM
L18
Long-Lasting Egg Consumption in Egg Allergic Children Treated with Oral Immunotherapy (OIT): Follow-up from the Consortium of Food Allergy Research (CoFAR) Study
Stacie M. Jones, MD
2:45 PM
L19
A Randomized, Double-Blind, Placebo-Controlled Trial of Omalizumab Combined with Oral Immunotherapy (OIT) in the Treatment of Cow's Milk Allergy (CMA): Safety of Dosing
Jennifer S. Kim, MD FAAAAI
3:00 PM
L20
Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
Thomas R.M. Bieber, MD PhD FAAAAI